Drug Profile


Alternative Names: UNII-00OLE78529; VX-765

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Aminobenzoic acids; Antipsoriatics; Dipeptides; Small molecules
  • Mechanism of Action Caspase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cardiovascular disorders; Epilepsy; Inflammation; Psoriasis

Most Recent Events

  • 31 Dec 2011 Vertex Pharmaceuticals initiates enrolment in a Phase-IIb trial for treatment-resistant epilepsy in USA (NCT01501383)
  • 02 Dec 2011 Adverse events and efficacy data from a phase II trial in Epilepsy presented at the 65th Annual Meeting of the American Epilepsy Society (AES-2011)
  • 10 Mar 2011 Efficacy and adverse events data from a phase II trial in Partial epilepsies released by Vertex Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top